Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
Torrent Pharmaceuticals and Novo Nordisk India opened a new greenfield insulin and parenteral facility at the former’s parenteral facility in Indrad, Gujarat, India, in December 2017.
The new facility was built as part of an agreement signed by Torrent Pharma with Novo Nordisk India in August 2005 to dedicate a part of its Indrad parenteral facility to carry out works related to insulin formulating and packaging.
The plant has been manufacturing insulin for Novo Nordisk products for more than 15 years. The new greenfield site will enable Novo Nordisk to meet the increasing demand for insulin products in India.
According to the International Diabetes Federation 8th Atlas, India has approximately 72.9 million people with diabetes, which is expected rise up to approximately 134.3 million by 2045. The new plant will enable Novo Nordisk to provide affordable and quality medication to address the growing challenge.
Details of the insulin and parenteral facility
The new facility incorporates state-of-art technology from the formulation of insulin to the packaging of insulin formulations. It has a systematic and single directional movement for both the people and material in the entire pharmaceutical area.
Provisions have been made for utilities such as WFI and Clean Steam Generator with capacities of 3m³/h and 800kg/h respectively. The civil structure of the facility was built using prefabricated modular partitions.
Products manufactured at the insulin and parental facility
Designed to comply with cGMP and EU GMP standards, the greenfield facility will produce insulin vials, lyophilised products and liquid ampoules/vials.
The existing Indrad parenteral facility has a capacity of 12.5 million insulin vials, 14.4 million vials of lyopholiser and 15 million ampoules. The new facility will increase the capacity to 15 million insulin vials and 30 million ampoules.
The plant’s initial capacity will be enough to meet the market demand for a period of five years, following which a second line is planned to be added. The plant’s capacity will be increased to 300 million insulin vials with the addition of the second line.
Details of the Indrad facility
The Indrad facility is built on a 194,000m² site, with a 46,000m² built-up area for formulations operations and 14,000m² for active pharmaceutical ingredients (API) operations.
Set up in 1989, the plant manufactures finished products in the oral, injectable and freeze-dried sterile injections form. It is compliant with various regulatory norms such as USFDA, WHO, cGMP and MHRA, and is also ISO-certified.
Marketing commentary on Novo Nordisk and Torrent Pharma
Based in Denmark, Novo Nordisk is a leading global healthcare company that has been involved in diabetes care for more than 90 years. It markets various treatments for obesity, haemophilia, growth disorders and other serious chronic diseases.
Novo Nordisk has more than 41,700 employees in 77 countries and has a global footprint in 165 countries. It partnered with Torrent Pharma in 1992 to manufacture insulin vials.
Apart from the Indrad plant, Torrent Pharma operates formulation and bulk drugs manufacturing plants at Baddi, Sikkim, Dahej, Pithampur and Vizag. The plants are approved by regulatory bodies of the US, UK, Brazil, Germany, Australia and South Africa.
Torrent also has a fully equipped research centre with approximately 900 scientists.
Thermo Fisher Scientific opened a new manufacturing facility in Lenexa, Kansas to meet the increasing demand for viral transport media…
Bushu Pharmaceuticals unveiled a new expansion programme for its pharmaceutical manufacturing facility in Misato, Japan, in August 2020. With the…